ADVERSE REACTIONS SECTION.

ADVERSE REACTIONS. The most frequent adverse reactions to Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup are: sedation; dryness of mouth, nose and throat; thickening of bronchial secretions; dizziness.Other adverse reactions may include:Dermatologic: Urticaria, drug rash, photosensitivity, pruritus.Cardiovascular System: Hypotension, hypertension, cardiac arrhythmias, palpitation.CNS: Disturbed coordination, tremor, irritability, insomnia, visual disturbances, weakness, nervousness, convulsions, headache, euphoria, and dysphoria.G.U. System: Urinary frequency, difficult urination.G.I. System: Epigastric discomfort, anorexia, nausea, vomiting, diarrhea, constipation.Respiratory System: Tightness of chest and wheezing, shortness of breath.Hematologic System: Hemolytic anemia, thrombocytopenia, agranulocytosis.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.

Carcinogenesis, Mutagenesis, Impairment of Fertility. Animal studies of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup to assess the carcinogenic and mutagenic potential or the effect on fertility have not been performed.

CLINICAL PHARMACOLOGY SECTION.

CLINICAL PHARMACOLOGY. Brompheniramine maleate is histamine antagonist, specifically an H1-receptor-blocking agent belonging to the alkylamine class of antihistamines. Antihistamines appear to compete with histamine for receptor sites on effector cells. Brompheniramine also has anticholinergic (drying) and sedative effects. Among the antihistaminic effects, it antagonizes the allergic response (vasodilation, increased vascular permeability, increased mucus secretion) of nasal tissue. Brompheniramine is well absorbed from the gastrointestinal tract, with peak plasma concentration after single, oral dose of mg reached in hours; urinary excretion is the major route of elimination, mostly as products of biodegradation; the liver is assumed to be the main site of metabolic transformation.Pseudoephedrine acts on sympathetic nerve endings and also on smooth muscle, making it useful as nasal decongestant. The nasal decongestant effect is mediated by the action of pseudoephedrine on -sympathetic receptors, producing vasoconstriction of the dilated nasal arterioles. Following oral administration, effects are noted within 30 minutes with peak activity occurring at approximately one hour.Dextromethorphan acts centrally to elevate the threshold for coughing. It has no analgesic or addictive properties. The onset of antitussive action occurs in 15 to 30 minutes after administration and is of long duration.

CONTRAINDICATIONS SECTION.

CONTRAINDICATIONS. Hypersensitivity to any of the ingredients. Do not use in the newborn, in premature infants, in nursing mothers, or in patients with severe hypertension or severe coronary artery disease. Do not use dextromethorphan in patients receiving monoamine oxidase (MAOI) inhibitors (see Drug Interactions).Antihistamines should not be used to treat lower respiratory tract conditions including asthma.

DESCRIPTION SECTION.

DESCRIPTION. Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup is clear, light pink syrup with butterscotch flavor.Each mL (1 teaspoonful) contains:Brompheniramine Maleate, USP ................. mgPseudoephedrine Hydrochloride, USP ........ 30 mgDextromethorphan Hydrobromide, USP ...... 10 mgAlcohol 0.95% v/vIn palatable, aromatic vehicle.Inactive Ingredients: alcohol, artificial butterscotch flavor, citric acid anhydrous, glycerin, methylparaben, propylene glycol, purified water, sodium benzoate, sodium citrate, sucrose, and FD&C Red No. 40. It may contain 10% citric acid solution or 10% sodium citrate solution for pH adjustment. The pH range is between 3.0 and 6.0.Antihistamine/Nasal Decongestant/Antitussive syrup for oral administration.. Chemical Structure 1. Chemical Structure 2. Chemical Structure 3.

DOSAGE & ADMINISTRATION SECTION.

DOSAGE AND ADMINISTRATION. Adults and pediatric patients 12 years of age and over: 10 mL (2 teaspoonfuls) every hours. Children to under 12 years of age: mL (1 teaspoonful) every hours. Children to under years of age: 2.5 mL 1/2 teaspoonful) every hours. Infants months to under years of age: Dosage to be established by physician.Do not exceed doses during 24-hour period.

DRUG INTERACTIONS SECTION.

Drug Interactions. Monoamine oxidase (MAO) inhibitorsHyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS).Central Nervous System (CNS) depressantsAntihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.).Antihypertensive drugsSympathomimetic may reduce the effects of antihypertensive drugs.

GENERAL PRECAUTIONS SECTION.

General. Because of its antihistamine component, Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup should be used with caution in patients with history of bronchial asthma, narrow angle glaucoma, gastrointestinal obstruction, or urinary bladder neck obstruction. Because of its sympathomimetic component, Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup should be used with caution in patients with diabetes, hypertension, heart disease, or thyroid disease.

HOW SUPPLIED SECTION.

HOW SUPPLIED. Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup is clear, light pink-colored, butterscotch-flavored syrup containing in each mL (1 teaspoonful) brompheniramine maleate mg, pseudoephedrine hydrochloride 30 mg and dextromethorphan hydrobromide 10 mg, available in the following sizes:4 fl oz (118 mL): NDC 0574-1104-041 Pint (473 mL): NDC 0574-1104-16.

INDICATIONS & USAGE SECTION.

INDICATIONS AND USAGE. For relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.

INFORMATION FOR PATIENTS SECTION.

Information for Patients. Patients should be warned about engaging in activities requiring mental alertness, such as driving car or operating dangerous machinery.

NURSING MOTHERS SECTION.

Nursing Mothers. Because of the higher risk of intolerance of antihistamines in small infants generally, and in newborns and prematures in particular, Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup is contraindicated in nursing mothers.

OVERDOSAGE SECTION.

OVERDOSAGE. Signs and SymptomsCentral nervous system effects from overdosage of brompheniramine may vary from depression to stimulation, especially in children. Anticholinergic effects may be noted. Toxic doses of pseudoephedrine may result in CNS stimulation, tachycardia, hypertension, and cardiac arrhythmias; signs of CNS depression may occasionally be seen. Dextromethorphan in toxic doses will cause drowsiness, ataxia, nystagmus, opisthotonos, and convulsive seizures.Toxic DosesData suggest that individuals may respond in an unexpected manner to apparently small amounts of particular drug. 2 1/2 -year-old child survived the ingestion of 21 mg/kg of dextromethorphan exhibiting only ataxia, drowsiness, and fever, but seizures have been reported in children following the ingestion of 13 mg/kg to 17 mg/kg. Another 1/2 -year-old child survived dose of 300 mg to 900 mg of brompheniramine. The toxic dose of pseudoephedrine should be less than that of ephedrine, which is estimated to be 50 mg/kg.TreatmentInduce emesis if patient is alert and is seen prior to hours following ingestion. Precautions against aspiration must be taken, especially in infants and small children. Gastric lavage may be carried out, although in some instances tracheostomy may be necessary prior to lavage. Naloxone hydrochloride 0.005 mg/kg intravenously may be of value in reversing the CNS depression that may occur from an overdose of dextromethorphan. CNS stimulants may counter CNS depression. Should CNS hyperactivity or convulsive seizures occur, intravenous short-acting barbiturates may be indicated. Hypertensive responses and/or tachycardia should be treated appropriately. Oxygen, intravenous fluids, and other supportive measures should be employed as indicated.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL 118 mL. Rx OnlyNDC 0574-1104-04Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide SyrupAlcohol 0.95% v/v4 FL OZ (118 mL)The following image is placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.. 118 mL label. serialization template.

PEDIATRIC USE SECTION.

Pediatric Use. Safety and effectiveness in pediatric patients below the age of months have not been established (see DOSAGE AND ADMINISTRATION).

PRECAUTIONS SECTION.

PRECAUTIONS. General. Because of its antihistamine component, Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup should be used with caution in patients with history of bronchial asthma, narrow angle glaucoma, gastrointestinal obstruction, or urinary bladder neck obstruction. Because of its sympathomimetic component, Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup should be used with caution in patients with diabetes, hypertension, heart disease, or thyroid disease.. Information for Patients. Patients should be warned about engaging in activities requiring mental alertness, such as driving car or operating dangerous machinery.. Drug Interactions. Monoamine oxidase (MAO) inhibitorsHyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS).Central Nervous System (CNS) depressantsAntihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.).Antihypertensive drugsSympathomimetic may reduce the effects of antihypertensive drugs.. Carcinogenesis, Mutagenesis, Impairment of Fertility. Animal studies of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup to assess the carcinogenic and mutagenic potential or the effect on fertility have not been performed.. Pregnancy. Teratogenic EffectsPregnancy Category CAnimal reproduction studies have not been conducted with Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup. It is also not known whether Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup can cause fetal harm when administered to pregnant woman or can affect reproduction capacity. It should be given to pregnant woman only if clearly needed.Reproduction studies of brompheniramine maleate (a component of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup) in rats and mice at doses up to 16 times the maximum human doses have revealed no evidence of impaired fertility or harm to the fetus.. Nursing Mothers. Because of the higher risk of intolerance of antihistamines in small infants generally, and in newborns and prematures in particular, Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup is contraindicated in nursing mothers.. Pediatric Use. Safety and effectiveness in pediatric patients below the age of months have not been established (see DOSAGE AND ADMINISTRATION).

PREGNANCY SECTION.

Pregnancy. Teratogenic EffectsPregnancy Category CAnimal reproduction studies have not been conducted with Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup. It is also not known whether Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup can cause fetal harm when administered to pregnant woman or can affect reproduction capacity. It should be given to pregnant woman only if clearly needed.Reproduction studies of brompheniramine maleate (a component of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Syrup) in rats and mice at doses up to 16 times the maximum human doses have revealed no evidence of impaired fertility or harm to the fetus.

STORAGE AND HANDLING SECTION.

RECOMMENDED STORAGE. Store at 20 to 25C (68 to 77F) [see USP Controlled Room Temperature].Keep Tightly ClosedDispense in tight, light-resistant container as defined in the USP.Rx Only. Manufactured By PerrigoMinneapolis, MN 5542722029420U400 RC J1Rev 04-14 A.

WARNINGS SECTION.

WARNINGS. Especially in infants and small children, antihistamines in overdosage may cause hallucinations, convulsions, and death.Antihistamines may diminish mental alertness. In the young child, they may produce excitation.